Sulfonylurea News and Research

RSS
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

No added benefit proven for empagliflozin in type 2 diabetes

No added benefit proven for empagliflozin in type 2 diabetes

Light-activated diabetes drug: an interview with Dr David Hodson

Light-activated diabetes drug: an interview with Dr David Hodson

Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

Scientists create light-activated drug to help control type 2 diabetes

Scientists create light-activated drug to help control type 2 diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

Type 2 diabetes Patients who take metformin plus insulin at higher risk for heart disease, death

Type 2 diabetes Patients who take metformin plus insulin at higher risk for heart disease, death

Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

New edition of RADAR includes review of glycopyrronium for COPD treatment

New edition of RADAR includes review of glycopyrronium for COPD treatment

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

DPP-4 inhibitors may reduce risk of autoimmune diseases

DPP-4 inhibitors may reduce risk of autoimmune diseases

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

IQWiG dossier assessment finds no added benefit of lixisenatide

IQWiG dossier assessment finds no added benefit of lixisenatide

Study finds that triple therapy corrects two core defects in type 2 diabetes

Study finds that triple therapy corrects two core defects in type 2 diabetes